Zinc Chloride


Exela Pharma Sciences,llc
Human Prescription Drug
NDC 51754-0102
Zinc Chloride is a human prescription drug labeled by 'Exela Pharma Sciences,llc'. National Drug Code (NDC) number for Zinc Chloride is 51754-0102. This drug is available in dosage form of Injection. The names of the active, medicinal ingredients in Zinc Chloride drug includes Zinc Chloride - 1 mg/mL . The currest status of Zinc Chloride drug is Active.

Drug Information:

Drug NDC: 51754-0102
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Zinc Chloride
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Prescription Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Zinc Chloride
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Exela Pharma Sciences,llc
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Injection
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:ZINC CHLORIDE - 1 mg/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:INTRAVENOUS
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: ANDA
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 27 Aug, 2021
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 21 Jan, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: ANDA212007
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Exela Pharma Sciences,LLC
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:237508
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:86Q357L16B
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class:Copper Absorption Inhibitor [EPC]
Decreased Copper Ion Absorption [PE]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
51754-0102-425 VIAL in 1 CARTON (51754-0102-4) / 10 mL in 1 VIAL27 Aug, 2021N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Product Elements:

Zinc chloride zinc chloride zinc chloride zinc cation sodium chloride sodium hydroxide hydrochloric acid

Indications and Usage:

Indications and usage zinc chloride injection, usp, 1 mg/ml is indicated for use as a supplement to intravenous solutions given for tpn. administration helps to maintain zinc serum levels and to prevent depletion of endogenous stores, and subsequent deficiency symptoms.

Warnings:

Warnings direct intramuscular or intravenous injection of zinc chloride injection, usp, 1 mg/ml is contraindicated as the acidic ph of the solution (2) may cause considerable tissue irritation. severe kidney disease may make it necessary to reduce or omit chromium and zinc doses because these elements are primarily eliminated in the urine. warning: this product contains aluminum that may be toxic. aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. tissue loading may occur at even lower rates of administration.

General Precautions:

General do not use unless the solution is clear and the seal is intact. zinc chloride injection, usp, 1 mg/ml should only be used in conjunction with a pharmacy directed admixture program using aseptic technique in a laminar flow environment; it should be used promptly and in a single operation without any repeated penetrations. solution contains no preservatives; discard unused portion immediately after admixture procedure is completed. zinc chloride injection, usp should not be given undiluted by direct injection into a peripheral vein because of the likelihood of infusion phlebitis and the potential for increased excretory loss of zinc from a bolus injection. administration of zinc in the absence of copper may cause a decrease in serum copper levels.

Dosage and Administration:

Dosage and administration zinc chloride injection, usp contains 1 mg/ml and is administered intravenously only after dilution. the additive should be diluted prior to administration in a volume of fluid not less than 100 ml. for the metabolically stable adult receiving tpn, the suggested intravenous dosage is 2.5 to 4 mg zinc/day (2.5 to 4 ml/day). an additional 2 mg zinc/day (2 ml/day) is suggested for acute catabolic states. for the stable adult with fluid loss from the small bowel, an additional 12.2 mg zinc/liter of small bowel fluid lost (12.2 ml/liter of small bowel fluid lost), or an additional 17.1 mg zinc/kg of stool or ileostomy output (17.1 ml/kg of stool or ileostomy output) is recommended. frequent monitoring of zinc blood levels is suggested for patients receiving more than the usual maintenance dosage level of zinc. for full term infants and children up to 5 years of age, 100 mcg zinc/kg/day (0.1 ml/kg/day) is recommended. for premature infants (birth weight less than 15
00 g) up to 3 kg in body weight, 300 mcg zinc/kg/day (0.3 ml/kg/day) is suggested. parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. (see precautions ).

Contraindications:

Contraindications none known.

Adverse Reactions:

Adverse reactions none known.

Use in Pregnancy:

Pregnancy animal reproduction studies have not been conducted with zinc chloride. it is also not known whether zinc chloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. zinc chloride should be given to a pregnant woman only if clearly needed.

Pediatric Use:

Pediatric use see dosage and administration section.

Geriatric Use:

Geriatric use an evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Overdosage:

Overdosage single intravenous doses of 1 to 2 mg zinc/kg body weight have been given to adult leukemic patients without toxic manifestations. however, acute toxicity was reported in an adult when 10 mg zinc was infused over a period of one hour on each of four consecutive days. profuse sweating, decreased level of consciousness, blurred vision, tachycardia (140/min), and marked hypothermia (94.2° f) on the fourth day were accompanied by a serum zinc concentration of 207 mcg/dl. symptoms abated within three hours. hyperamylasemia may be a sign of impending zinc overdosage; patients receiving an inadvertent overdose (25 mg zinc/liter of tpn solution, equivalent to 50 to 70 mg zinc/day) developed hyperamylasemia (557 to 1850 klein units; normal: 130 to 310). death resulted from an overdosage in which 1683 mg zinc was delivered intravenously over the course of 60 hours to a 72-year-old patient. symptoms of zinc toxicity included hypotension (80/40 mm hg), pulmonary edema, diarrhea, vomiting, jaundice, and oliguria, with a serum zinc level of 4184 mcg/dl. calcium supplements may confer a protective effect against zinc toxicity.

Description:

Description zinc chloride injection, usp, 1 mg/ml is a sterile, nonpyrogenic solution intended for use as an additive to intravenous solutions for total parenteral nutrition (tpn). each ml of solution contains 2.09 mg zinc chloride and 9 mg sodium chloride. the solution contains no bacteriostat, antimicrobial agent or added buffer. the ph is 2.0 (1.5 to 2.5); product may contain hydrochloric acid and sodium hydroxide for ph adjustment. the osmolarity is 0.354 mosmol/ml (calc.). zinc chloride, usp is chemically designated zncl 2 , a white crystalline compound freely soluble in water. sodium chloride, usp is chemically designated nacl, a white crystalline compound freely soluble in water. the semi-rigid vial is fabricated from a specially formulated polyolefin. it is a copolymer of ethylene and propylene. the safety of the plastic has been confirmed by tests in animals according to usp biological standards for plastic containers. the small amount of water vapor that can pass through the plastic container wall will not significantly alter the drug concentration.

Clinical Pharmacology:

Clinical pharmacology zinc is an essential nutritional requirement and serves as a cofactor for more than 70 different enzymes including carbonic anhydrase, alkaline phosphatase, lactic dehydrogenase, and both rna and dna polymerase. zinc chloride injection, usp facilitates wound healing, helps maintain normal growth rates, normal skin hydration, and the senses of taste and smell. zinc chloride injection, usp resides in muscle, bone, skin, kidney, liver, pancreas, retina, prostate and particularly in the red and white blood cells. zinc chloride injection, usp binds to plasma albumin, α 2 -macroglobulin, and some plasma amino acids including histidine, cysteine, threonine, glycine, and asparagine. ingested zinc is excreted mainly in the stool (approximately 90%), and to a lesser extent in the urine and in perspiration. providing zinc helps prevent development of deficiency symptoms such as: parakeratosis, hypogeusia, anorexia, dysosmia, geophagia, hypogonadism, growth retardation and
hepatosplenomegaly. the initial manifestations of hypozincemia in total parenteral nutrition are diarrhea, apathy and depression. at plasma levels below 20 mcg zinc/100 ml dermatitis followed by alopecia has been reported for total parenteral nutrition patients. normal zinc plasma levels are 100 ± 12 mcg/100 ml.

Carcinogenesis and Mutagenesis and Impairment of Fertility:

Carcinogenesis, mutagenesis, impairment of fertility long-term animal studies to evaluate the carcinogenic potential of zinc chloride injection, usp, 1 mg/ml have not been performed, nor have studies been done to assess mutagenesis or impairment of fertility.

How Supplied:

How supplied zinc chloride injection, usp, 1 mg/ml is supplied in 10 ml plastic vials. ndc number strength packaged ndc 51754-0102-1 10 mg/10 ml (1 mg/ml) 10 ml vial ndc 51754-0102-4 10 mg/10 ml (1 mg/ml) 25 vials per carton store at 20 to 25°c (6 8 to 77°f). [see usp controlled room temperature.] manufactured and distributed by: 1245 blowing rock blvd lenoir, nc 28645 revised 05/2021 exela logo

Package Label Principal Display Panel:

Package/label principal display panel-10 ml vial label rx only ndc 51754-0102-1 zinc chloride injection, usp 10 mg/10 ml (1mg/ml) for intravenous use only after dilution discard unused portion 10 ml single-dose vial vial label

Package/label principal display panel-25 ct carton ndc 51754-0102-4 rx only zinc chloride injection, usp 10 mg/10 ml (1 mg/ml) caution: for intravenous use only after dilution discrd unused portion 25 x 10 ml single-dose vials carton label


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.